Oral GLP-1

Oral GLP-1 Analogue

 

Primary Indication

Treatment of Type 2 diabetes mellitus

 

Stage of Development

 

Entering Phase I/IIa

  • Outlicensing opportunity - providing oral formulation technology to GLP-1 analogue
  • Stimulates insulin formation and release when blood glucose levels are high
  • Reduces glucose output from the liver
  • Improves insulin sensitivity and the function of ß-cells
  • Slows emptying of stomach and reduces desire to eat
Print Print | Sitemap
© 2021, Diabetology Ltd | Privacy Policy | Terms & Conditions | Copyright